EngNT demonstrates equivalent performance to autograft in preclinical nerve repair

Important new study provides compelling preclinical evidence to support the effectiveness of Engineered Neural Tissue (EngNT) as a replacement for the nerve autograft. Functional regeneration assessed through histological and electrophysiological outcome measures demonstrated equivalent performance. Furthermore, the living replacement nerve tissue was implanted within a collagen membrane wrap, providing an artificial tissue with similar mechanical and handling properties to natural nerve.

This study will help underpin progression of the technology through the required manufacture and regulatory steps to testing in human patients. Translation of EngNT to clinical application is being undertaken with our UCL spinout company Glialign Ltd.